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Histamine-1 (H1) antihistamines are the ®rst-line
drug for the treatment of urticaria. Major progress
has been achieved in recent years both in the under-
standing of their ligands, the H1-histamine receptors,
and therefore in the mechanisms of their pharmaco-
logic effects, as well as in the development of safer
antihistamines with low or no sedating effects and no
interactions on the level of potassium channels lead-
ing to QT-prolongations and interactions on the
level of cytochrome P450 isoenzymes. This develop-
ment has brought antihistamines very close to the
ideal antihistamines that are desired by clinicians to
treat most types of urticaria in patients who have to
take these drugs for a long time. Key words: antihist-
amines/cytochrome P450/urticaria. Journal of Investigative
Dermatology Symposium Proceedings 6:153±156, 2001
H
istamine-1 (H1) antihistamines are the ®rst-line drug
for the treatment of urticaria. They all competively
inhibit the binding of released histamine on H1
receptors and thus decrease the incidence of wheals
and the intensity of itching. The pharmacologist
Holtz, who found that norepinephrine is a physiologic compound,
once remarked: ``What would be pharmacology without epi-
nephrine, and what would be epinephrine without pharmacology.''
He underlined the importance of this compound for the under-
standing of ligand±receptor interactions for pharmacologic activities
of small molecular weight compounds. Antihistamines play a similar
role in dermatopharmacology and allergology as epinephrine plays
in pharmacology. This is highlighted by the fact that Sir Henry
Dale, who found that histamine alone can induce the triple
response erythema, wheals, and itching, and Bovet, who developed
the ®rst antihistamine, were awarded the Nobel prize (Emanuel,
1999).
In recent years Yamashita et al have succeeded in cloning the
gene encoding for the bovine H1 receptor, and subsequently this
sequence information was used to clone the H1-receptor gene of
humans, which is a protein of 487 amino acids (Chowdhury and
Kaliner, 1996). This receptor belongs to the family of G protein
coupled receptors, which is the largest receptor family, including
more than 150 different receptors such as the histamine-1 and -2,
the adrenergic, or the muscarinic acetylcholine receptors.
Interestingly, in humans the H1 receptor and the muscarinic
acetylcholine receptor possess the highest sequence similarity of
about 45% in the G protein coupled receptor family, which might
explain the cholinergic-like side-effects of some antihistamines.
The gene of the H1 receptor is localized on chromosome 3 in
humans and close to the gene of the interleukin 5a-receptor
(Chowdhury and Kaliner, 1996; Leurs et al, 1996). G-protein-
coupled receptors are characterized by seven transmembrane
domains, which transverse the membrane in an a-helical con®g-
uration with three alternating extracellular and intracellular loops
that connect the transmembrane region. The amino-terminal end
of the receptor-protein is extracellular, the carboxy-terminal
intracellular (Fig 1). The signaling pathway that is mediated by
G proteins is dependent on a facilitated exchange of GTP for
bound GDP after an agonist has bound to the receptor.
The binding of histamine to H1 receptors in the skin induces the
vascular endothelium to release nitric oxide, which stimulates
guanyl cyclase and increases cyclic guanosine monophosphate in
the vascular smooth muscle, which results in vasodilation, increased
vascular permeability, edema formation, and erythema.
H1-blocking agents generally share certain structural features.
These include a substituted ethylamine moiety and a tertiary amino
group linked by a two- or three-atom chain to two aromatic
groups. Tricyclic derivatives exist in which the two aromatic rings
are bridged. X is a nitrogen or carbon atom or a C-O ether bridge
to the a-aminoethyl side-chain (Merk and Bickers 1992).
The H1 antihistamines are widely used in dermatologic therapy
for the symptomatic relief of the cutaneous manifestations of a
variety of allergic disorders (Merk and Bickers 1992). These agents
can be divided into several groups, as listed in Table I. In general,
they have similar properties and the choice of an agent will depend
on factors other than pharmacologic ef®cacy, including side-effects
and cost. The effects of antihistamines in urticaria have been shown
in numerous clinical studies (Sim and Grant, 1996; Simons, 2000;
Simpson and Jarvis 2000; Tharp, 2000). The suppression of itching
in urticaria is stronger than in other skin diseases with itching, such
as atopic dermatitis (Fig 2) (StuÈttgen, 1984; Henz et al, 1998).
Their effect is limited, especially in pressure urticaria and severe
forms of autoimmuneurticaria; however, after treatment of, for
example, autoimmune urticaria with cyclosporine, antihistamines
can be helpful in the case of a relapse of this condition (Grattan et al,
2000). In the treatment of cholinergic urticaria, antihistamines with
a strong anticholinergic effect such as hydroxyzine may be helpful;
however, apart from emergency cases in which antihistamines that
can be given intravenously, such as clemastine or diphenhydramine,
are used, today antihistamines without sedative effects are preferred
(Table II).
SAFETY OF H1 ANTIHISTAMINES
As antihistamines are often taken for long periods, the ideal
antihistamine for urticaria should show high ef®cacy, no tachy-
phylaxis, and a good safety pro®le, with no cardiotoxic effects and
no clinically signi®cant drug interaction (Timmerman, 2000).
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Histamine functions as a neurotransmitter and it is particularly
important in maintaining a state of arousal or awareness within the
central nervous system (CNS) (Yanai et al, 1995). H1 receptors are
present in the CNS and they are especially expressed in the cerebral
cortex, striatum, hypothalamus, olfactory tubercles, olfactory bulb,
and pituitary gland (Chowdhury and Kaliner, 1996). Therefore the
®rst, highly lipophilic antihistamines possess sedative effects as a
major side-effect. This problem was overcome by the development
of so-called second-generation antihistamines ± ter®nadine was the
®rst one of them ± that did not enter the CNS and therefore
exerted no or markedly reduced sedative effects. These differencies
between ®rst-generation and second-generation antihistamines
were elegantly demonstrated by PET studies, showing a reduced
interaction of ter®nadine and its metabolites with these CNS-
located H1 receptors (Fig 3) (Yanai et al, 1995).
Drug interactions between antihistamines and other drugs may
occur on several different levels. Antihistamines with strong
anticholinergic effects such as hydroxizine inhibit gastrointestinal
motility, thereby reducing the rate of intestinal absorption of other
drugs (Roos and Merk, 2000). Although the total amount of
absorbed drug is not reduced, the retarded resorption of drugs such
as analgesics can lead to a critical change in the distribution of a
drug between neural and fat tissue and lowered therapeutic
concentration. More attention was drawn to interactions of
antihistimes and other drugs on the level of drug-metabolizing
enzymes such as cytochrome P450 (CYP). The genes of these
isoenzymes belong to a supergene family that is considered to be
the largest known gene family. These enzymes metabolize small
molecular weight compounds such as xenobiotica-including drugs.
In humans most drugs are metabolized by the isoenzyme CYP3A4.
In the case of ter®nadine and astemizole an interaction on the level
of CYP3A4-dependent metabolism was observed with, for
example, ketoconazole, itraconazole, and erythromycin. This
interaction can increase the concentration of terfenadine and
thereby its interaction with the cardiac potassium channel leading
to a QT-prolongation and the torsade-de-pointe arrythmias
(Woosley, 1996). This particular problem was solved by the
replacement of terfenadine by its metabolite fexofenadine, which
acts as an antihistamine without having these problems. At this time
fexofenadine and ceterizine ± derived from hydroxyzine ± are the
two antihistamines that are not metabolized by CYP (Simpson and
Jarvis, 2000). The metabolite of loratadine ± desloratadine ± will
become available soon.1 Many other antihistamines such as
loratadine or mizolastine are also metabolized by CYP3A4, but as
in these cases they can also be metabolized by other CYP-
isoenzymes such as CYP2D6, and therefore an inhibition of
CYP3A4 can be bypassed. Furthermore, loratadine does not have a
Figure 1. H1 receptores belong to the G-
protein coupled receptor family. (Adapted
from Chowdhury and Kaliner, 1996.)
Figure 2. Antihistamines have a stronger effect on itching in
urticaria than in other skin diseases such as atopic dermatitis.
(Adapted from Henz et al, 1998.)
Figure 3. In this PET analysis of H1-histamine receptors is the
different effect by the nonsedating antihistamine terfenadine in
comparison with the sedating antihistamine chlorpheniramine on
CNS H1 receptors shown. (Adapted from Yanai et al, 1995.)
1Kreutner W, Hey JA, Anthes J, Barnett A, Tozzi S: Preclinical ef®cacy
and antiallergic pro®le of desloratadine, a selective and nonsedating
Histamine H1-receptor antagonist. J Allergy Clin Immunol 105:382, 2000
(abstr.)
Table I. Major chemical groups of class 1 H1
antihistamines
Ethylendiamines (e.g., pyrilamine)
Ethanolamines (e.g., diphenhydramine)
Alkylamines (e.g., chlorphehydramine)
Phenothiazines (e.g., promethazine)
Piperazines (e.g., cyclizine, hydroxyzine)
Piperidines (azatadine)
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similar interaction with the cardiac potassium channel as ter®na-
dine.
Teratogenic effects have been noted in response to piperazine
compounds, but extensive clinical studies have not demonstrated
any association between the use of such antihistamines and fetal
anomalies in humans (Garrison et al, 1990).
ANTIALLERGIC EFFECTS OF H1-RECEPTOR
ANTAGONISTS
When Bovet found the ®rst compounds that possessed antihist-
amine-like activity, he was searching for drugs with anticholinergic
activities, and several antihistamines also possess these. Therefore
they are not H1-receptor speci®c but only selective (Church et al,
1996). On the other hand signs and symptoms of allergic diseases
including urticaria are not only mediated by histamine, and
therefore it is of interest whether some antihistamines have more
antiallergic activities than just the inhibition of histamine by
preventing its binding to H1 receptors. As early as 1953 it was
reported that antihistamines might have the capability to inhibit the
release of histamine from mast cells and basophils (Arunlakshana
and Schild, 1953). Subsequent studies revealed that antihistamines
are able to inhibit IgE-dependent release of histamines in low
concentrations independently from their H1-receptor antagonism,
and that the lipophilicity of the antihistamines is a main factor that
determines this effect. It has been suggested that the dissoving of the
lipophilic end of the molecule in the cell membrane leads to the
presentation of a positive charge on the outside of the cell
membrane, this competetively inhibits the binding of calcium to
the membrane, which subsequently reduces the calcium transport
through the membrane, and therefore diminishes the activity of
calcium-dependent enzymes such as calmodulin (Church et al,
1996). On the other hand, at high concentrations the expansion of
the cell membrane increases by the solved antihistamines and this
leads ®nally to an increase of histamine release. Therefore the
concentration of the antihistamine under clinical conditions
determines whether it inhibits or increases the histamine release
from basophiles and mast cells, and this may differ from one
antihistamine to another. There are several models that allow to
determine this capability of antihistamines under clinical conditions
(Nacliero and Baroody, 1996). One model are the physical
urticaria, in particular the cold urticaria, because it is possible to
induce this disease under experimental conditions. In one such
experiment we studied four female patients aged 19±46 y with
acquired cold urticaria of 1 mo to 24 y duration. The patients had
been off all drugs for 7 d. On day 0, blood was taken from the
antecubital veins and the hands were immersed in cold water at 5°C
for 10 min. Further blood samples were taken 2, 5, 20, and 30 min
after the end of the cold challenge for the histamine assay. From day
1 to day 7 ketotifen (2 mg per d) or oxatomide (60 mg per d) was
taken. On day 7, 2 h after the last administration of the drug the
cold challenge at the histamine assays were repeated. No drug was
given on days 8±14 and on days 15±21 the alternative antihistamine
ketotifen or oxatomide was administered. On day 21 cold challenge
and histamine assays were performed once more. For the histamine
assay, blood was taken and after centrifugation plasma was taken off
and the histamine concentration was measured with a technicon
analyzer after precipitation with 2 N perchloric acid. In all patients
the histamine content increased after cold challenge on the side that
was challenged with cold water compared with the nonchallenged
side, and after the pretreatment with ketotifen or oxatomide the
histamine concentration decreased. The mean value was 45.8%
after ketotifen and 23.8% after oxatomide (Merk et al, 1985).
Beside its role as mediator of early onset type allergic reactions
and promotor of gastric acid secretion, histamine is reported to
modulate cellular and humoral immune responses (Sachs et al,
2000). It has been suggested with regard to certain diseases that are
associated with increased histamine concentrations, like atopy or
chronic gastritis, that histamine induces or promotes a shift from a
Th1 to a Th2 immune response (Beer and Rocklin, 1987);
however, the effects of histamine receptor antagonists on
lymphocytes as the main actors in the immune response is only
poorly understood (Munakata et al, 1999). Further effects on other
cells or mediators that participate in in¯ammatory reactions such as
eosinophils, adhesion proteins such as ICAM-1, or cytokines such
as TNFa, interleukin 5, platelet activating factor, or leukotrienes,
have been reported; however, their clinical signi®cance at thera-
peutic concentrations of antihistamines remains controversial
(Church et al, 1996).
Taken together the development of antihistamines (i) without
in¯uencing CNS effects of histamine and (ii) with no interactions
on the level of the potassium channel of membranes with the risk of
QT-prolongation as well as on the level of CYP-isoenzymes, has
brought H1 antihistamines very close to the ideal antihistamines
which are desired by clinicians to treat most types of urticaria in
patients who have to take these drugs for a long time.
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